Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 3/20 | 0.39 |
| ▸ | AKT1 | P31749 | 13/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799671 | 0.88 | GAA (0.50) | FPR1AKT1FPR2ALDH1A1GAA | |
| SCHEMBL17799658 | 0.84 | FPR1 (0.37) | FPR1AKT1FPR2NPC1RAB9A | |
| SCHEMBL17799697 | 0.83 | NPC1 (0.40) | ALDH1A1GAAMAPTAGTR1TDP1 | |
| SCHEMBL17799650 | 0.81 | FPR1 (0.38) | FPR1AKT1FPR2GRIA4NPC1 | |
| SCHEMBL17799740 | 0.79 | FPR1 (0.37) | FPR1AKT1FPR2GRIA4NPC1 | |
| SCHEMBL17799635 | 0.78 | L3MBTL1 (0.46) | FPR1FPR2ALDH1A1MEN1NPC1 | |
| SCHEMBL17799687 | 0.77 | AKT1 (0.38) | FPR1AKT1FPR2 | |
| SCHEMBL20298565 | 0.75 | AKT1 (0.38) | FPR1AKT1FPR2 | |
| SCHEMBL17799735 | 0.74 | LMNA (0.54) | ALDH1A1GAAMAPTNPC1RAB9A | |
| SCHEMBL17799721 | 0.74 | HCRTR1 (0.47) | FPR1AKT1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50724-E1 | 4-membered ring carboxamides used as nematicides | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-3019476-B1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | TUBA3C, DDT, CYCS | FPR1 605/4885AKT1 4061/4885FPR2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.